Loading...

Pacific Blue™ anti-human CD45 Antibody

Pricing & Availability
Clone
HI30 (See other available formats)
Regulatory Status
RUO
Workshop
IV N816
Other Names
LCA, T200
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
HI30_Blue_021508
Human peripheral blood lymphocytes stained with HI30 Pacific Blue™
  • HI30_Blue_021508
    Human peripheral blood lymphocytes stained with HI30 Pacific Blue™
See Pacific Blue™ spectral data
Cat # Size Price Quantity Check Availability Save
304021 25 µg 100€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
304022 100 µg 212€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
304029 100 tests 212€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD45 is a 180-240 kD single chain type I membrane glycoprotein also known as leukocyte common antigen (LCA) and T200. It is a tyrosine phosphatase expressed on the plasma membrane of all hematopoietic cells, except erythrocytes and platelets. CD45 is a signaling molecule that regulates a variety of cellular processes including cell growth, differentiation, cell cycle, and oncogenic transformation. CD45 plays a critical role in T and B cell antigen receptor-mediated activation by dephosphorylating substrates including p56Lck, p59Fyn, and other Src family kinases. CD45 non-covalently associates with lymphocyte phosphatase-associated phosphoprotein (LPAP) on T and B lymphocytes. CD45 has been reported to bind galectin-1 and to be associated with several other cell surface antigens including CD1, CD2, CD3, and CD4.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Human
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
test size: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
µg size: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with Pacific Blue™ under optimal conditions.
Concentration
µg sizes: 0.5 mg/mL
test sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis.
For test size, the suggested use of this reagent for immunofluorescent staining is 5 µl per 106 cells in 100 µl volume.
For µg sizes, the suggested use of this reagent for immunofluorescent staining is ≤0.5 µg per 106 cells in 100 µl volume.
It is recommended that the reagent be titrated for optimal performance for each application.

* Pacific Blue™ has a maximum emission of 455 nm when it is excited at 405 nm. Prior to using Pacific Blue™ conjugate for flow cytometric analysis, please verify your flow cytometer's capability of exciting and detecting the fluorochrome.


Alexa Fluor® and Pacific Blue™ are trademarks of Life Technologies Corporation.

View full statement regarding label licenses
Excitation Laser
Violet Laser (405 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections and formalin-fixed paraffin-embedded tissue sections9, inhibition of CD45 functions4, immunofluorescence11, Western blotting3, and spatial biology (IBEX)16,17.

It was found that the HI30 clone and the 2D1 clone can cross block each other's binding.

Application References
  1. Knapp W, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York.
  2. Kishihara K, et al. 1993. Cell 74:143.
  3. Esser M, et al. 2001. J. Virol. 75:6173. (WB)
  4. Yamada T, et al. 2002. J. Biol. Chem. 277:28830.
  5. Nagano M, et al. 2007. Blood 110:151.
  6. Jiang Q, et al. 2008. Blood 112:2858. PubMed
  7. Morozov A, et al. 2010. Clin Cancer Res. 16:5630. PubMed
  8. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  9. Friedman T, et al. 1999. J. Immunol. 162:5256. (IHC)
  10. Oeztuerk-Winder F, et al. 2012. EMBO J. 31:3431. (FC) PubMed
  11. Rees LE, et al. 2003. Clin. Exp. Immunol. 134:497. (IF)
  12. Lee J, et al. 2015. J Exp Med. 212:385. PubMed
  13. Breton G, et al. 2015. J Exp Med. 212:401. PubMed
  14. Marquardt N, et al. 2015. J Immunol. 6:2467. PubMed
  15. Bushway ME, et al. 2014. Biol Reprod. 90(5): 110. (IF) PubMed
  16. Radtke AJ, et al. 2020. Proc Natl Acad Sci USA. 117:33455-33465. (SB) PubMed
  17. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Narasimhan PB, et al. 2018. PLoS Negl Trop Dis. 12:e0006404. PubMed
  2. Du X, et al. 2018. Cell Res. 28:416. PubMed
  3. Tyurin-Kuzmin PA, et al. 2018. Sci Data. 5:180196. PubMed
  4. Tcymbarevich IV, et al. 2019. BMC Gastroenterol. 19:2. PubMed
  5. Schiroli G et al. 2019. Cell stem cell. 24(4):551-565 . PubMed
  6. Beringer A, et al. 2019. Sci Rep. 9:8378. PubMed
  7. Zhang Y, et al. 2019. Cell Res. 29:609. PubMed
  8. Okumura T, et al. 2019. Stem Cell Res Ther. 10:185. PubMed
  9. Logan PC, et al. 2018. Reprod Sci. 25:140. PubMed
  10. Santoni de Sio FR, et al. 2018. J Allergy Clin Immunol. 142:1909. PubMed
  11. Tomellini E, et al. 2020. Cell Reports. 28(4):1063-1073.e5.. PubMed
  12. Queckborner S, et al. 2020. Stem Cell Res Ther. 11:15. PubMed
  13. Li S, et al. 2020. Commun Biol. 3:26. PubMed
  14. Zah E, et al. 2020. Nat Commun. 11:2283. PubMed
  15. Li J, et al. 2017. Toxicology. 378:17. PubMed
  16. Zimmerman KA, et al. 2019. J Am Soc Nephrol. 30:767. PubMed
  17. Carter BZ, et al. 2019. Cancer Res. 79:1165. PubMed
  18. Baccelli I, et al. 2020. Cancer Cell. 36(1):84-99. PubMed
  19. Legrand F, et al. 2019. J Allergy Clin Immunol. 143:2227. PubMed
  20. Rizzo MD, et al. 2019. J Neuroimmunol. 333:576969. PubMed
  21. Lu Y, et al. 2020. Cell. 180(6):1081-1097. PubMed
  22. Shin JJ, et al. 2020. Cell Rep. 32:108093. PubMed
  23. Rizzo MD, et al. 2019. J Pharmacol Exp Ther. 371:191. PubMed
  24. Lu Y, et al. 2020. STAR Protoc. 1:100040. PubMed
  25. Goodnough LH, et al. 2020. JBMR Plus. 4:e10398. PubMed
  26. Morozov A, et al. 2010. Clin Cancer Res. 4.576388889. PubMed
  27. Chou S, et al. 2012. Proc Natl Acad Sci U S A. 109:17573. PubMed
  28. Hofner T, et al. 2014. Urol Oncol. 32:678. PubMed
  29. Gleason M, et al. 2014. Blood. 123:3016. PubMed
  30. Valle A, et al. 2015. J Immunol. 194:2117. PubMed
  31. Cheah M, et al. 2015. Proc Natl Acad Sci U S A. 112:4725. PubMed
  32. Stoeckle C, et al. 2013. J Vis Exp. 79: 50951. PubMed
  33. Krampitz G, et al. 2016. Proc Natl Acad Sci U S A. 113: 4464-4469. PubMed
  34. Pham K, et al. 2016. Am J Pathol. 186: 1537-1546. PubMed
  35. Griffiths K, et al. 2016. J Biol Chem. 291: 12641 - 12657. PubMed
  36. Iannetta M, et al. 2016. PLoS One. 11: 0160277. PubMed
  37. Skowron K, et al. 2016. Sci Rep. 6:35854. PubMed
  38. Ângela Crespo, Jack Strominger, Tamara Tilburgs 2016. Proc Natl Acad Sci U S A. 113(52):15072-15077. PubMed
  39. Marsden MD, et al. 2020. Cell Rep Med. 1:100162. PubMed
  40. Ambrosi TH, et al. 2020. Aging Cell. 19:e13164. PubMed
  41. Jandke A, et al. 2020. Nat Commun. 3.075694444. PubMed
  42. Borrelli MR, et al. 2020. Stem Cells Transl Med. 1.347916667. PubMed
  43. Borrelli MR, et al. 2020. Stem Cells Transl Med. 1.339583333. PubMed
  44. Chen Z, et al. 2020. Int J Biol Sci. 2.197916667. PubMed
  45. Iwabuchi R, et al. 2021. Frontiers in Immunology. 12:643040. PubMed
  46. Ferrari S, et al. 2021. Nature Protocols. 16(6):2991-3025. PubMed
  47. Luoma AM, et al. 2020. Cell. 182(3):655-671.e22. PubMed
  48. Mender I, et al. 2020. Cancer Cell. 38(3):400-411.e6. PubMed
  49. Chagraoui J, et al. 2021. Cell Stem Cell. 28(1):48-62.e6. PubMed
  50. Riether C, et al. 2021. Cell Reports. 34(4):108663. PubMed
  51. Mathewson ND, et al. 2021. Cell. 184(5):1281-1298.e26. PubMed
  52. Kenswil KJG, et al. 2021. Cell Stem Cell. 28(4):653-670.e11. PubMed
  53. Bonifacius A, et al. 2021. Immunity. 54(2):340-354.e6. PubMed
  54. Caduff N, et al. 2021. Cell Reports. 35(5):109056. PubMed
  55. Zee BM, et al. 2021. iScience. 24(6):102651. PubMed
  56. Borrelli MR, et al. 2020. Aesthet Surg J. 369:40. PubMed
  57. Pache L, et al. 2020. Cell Rep Med. 1:100037. PubMed
  58. Frangieh CJ, et al. 2021. Nat Genet. 53:332. PubMed
  59. Rademacher MJ, et al. 2021. Sci Rep. 11:8321. PubMed
  60. Carre C, et al. 2021. iScience. 24:102970. PubMed
  61. Hinterbrandner M, et al. 2021. JCI Insight. 6:e151797. PubMed
  62. Gussarow D, et al. 2021. Front Med (Lausanne). 8:770381. PubMed
  63. Sefik E, et al. 2021. Nat Biotechnol. . PubMed
  64. Twigger AJ, et al. 2022. Nat Commun. 13:562. PubMed
  65. Phansalkar R, et al. 2021. Elife. 10:. PubMed
  66. He L, et al. 2022. EMBO Mol Med. 14:e14990. PubMed
  67. Bohnert KL, et al. 2020. Foot Ankle Int. 41:536. PubMed
  68. Morgan MA, et al. 2021. Viruses. 13:. PubMed
  69. Deleon NMD, et al. 2021. J Tissue Eng Regen Med. 15:1105. PubMed
  70. Moison C, et al. 2022. Blood Adv. 6:4793. PubMed
  71. Castañeda-Partida L, et al. 2022. Discov Oncol. 13:28. PubMed
  72. Li H, et al. 2022. Cell Rep Med. 3:100554. PubMed
  73. Sefik E, et al. 2022. Nature. 606:585. PubMed
  74. Omer-Javed A, et al. 2022. Cell. 185:2248. PubMed
  75. Shishkova D, et al. 2022. Int J Mol Sci. 23: . PubMed
  76. Li K, et al. 2023. Leukemia. 37:308. PubMed
  77. Lu T, et al. 2023. Cancer Immunol Immunother. :. PubMed
  78. Ali LR, et al. 2023. J Exp Med. 220: . PubMed
  79. Zhang B, et al. 2023. Signal Transduct Target Ther. 8:28. PubMed
  80. Jaiswal A, et al. 2022. Cancer Cell. 40:524. PubMed
  81. Lee KM, et al. 2022. Cancer Immunol Res. 10:829. PubMed
  82. Svec J, et al. 2022. Cancers (Basel). 14:. PubMed
  83. Zheng Y, et al. 2022. Proc Natl Acad Sci U S A. 119:e2121077119. PubMed
  84. Jun SH, et al. 2023. Nat Commun. 14:982. PubMed
  85. Pan X, et al. 2022. Cell Mol Biol (Noisy-le-grand). 68:77. PubMed
  86. Kameishi S, et al. 2023. Sci Rep. 13:4421. PubMed
  87. Pelletier J, et al. 2023. iScience. 26:106385. PubMed
  88. Saez-Ayala M, et al. 2023. Nat Commun. 14:3079. PubMed
  89. Hoover MY, et al. 2023. Nat Protoc. . PubMed
  90. Gopalakrishnapillai A, et al. 2021. Cancers (Basel). 13:. PubMed
RRID
AB_493654 (BioLegend Cat. No. 304021)
AB_493655 (BioLegend Cat. No. 304022)
AB_2174123 (BioLegend Cat. No. 304029)

Antigen Details

Structure
Tyrosine phosphatases, type I transmembrane protein, 180-240 kD (multiple isoforms)
Distribution

Hematopoietic cells, not expressed in circulating erythrocytes or platelets

Function
TCR and BCR mediated activation
Ligand/Receptor
Galectin-1, CD2, CD3, CD4
Cell Type
Hematopoietic stem and progenitors, Mesenchymal Stem Cells
Biology Area
Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers, Stem Cells
Molecular Family
CD Molecules
Antigen References
  1. Thomas M. 1989. Annu. Rev. Immunol. 7:339.
  2. Trowbridge I, et al. 1994. Annu. Rev. Immunol.12:85.
Gene ID
5788 View all products for this Gene ID
UniProt
View information about CD45 on UniProt.org

Related FAQs

There are no FAQs for this product.

Customers Also Purchased

FITC anti-human CD45
Clone: HI30

APC anti-human CD3
Clone: UCHT1

PE anti-human CD45
Clone: HI30

FITC anti-human CD3
Clone: UCHT1

Go To Top Version: 2    Revision Date: 04/25/2013

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account